136 related articles for article (PubMed ID: 38526957)
1. Physical signs and atherosclerotic cardiovascular disease in familial hypercholesterolemia: the HELLAS-FH Registry.
Rallidis LS; Rizos CV; Papathanasiou KA; Liamis G; Skoumas I; Garoufi A; Kolovou G; Tziomalos K; Skalidis E; Kotsis V; Sfikas G; Doumas M; Anagnostis P; Lambadiari V; Giannakopoulou V; Kiouri E; Anastasiou G; Petkou E; Koutagiar I; Attilakos A; Kolovou V; Zacharis E; Antza C; Koumaras C; Boutari C; Liberopoulos E
J Cardiovasc Med (Hagerstown); 2024 May; 25(5):370-378. PubMed ID: 38526957
[TBL] [Abstract][Full Text] [Related]
2. Obesity and atherosclerotic cardiovascular disease in adults with heterozygous familial hypercholesterolemia: An analysis from HELLAS-FH registry.
Barkas F; Rizos CV; Liamis G; Skoumas I; Garoufi A; Rallidis L; Kolovou G; Tziomalos K; Skalidis E; Sfikas G; Kotsis V; Doumas M; Anagnostis P; Lambadiari V; Anastasiou G; Koutagiar I; Attilakos A; Kiouri E; Kolovou V; Polychronopoulos G; Koutsogianni AD; Zacharis E; Koumaras C; Antza C; Boutari C; Liberopoulos E
J Clin Lipidol; 2024; 18(3):e394-e402. PubMed ID: 38331687
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with the presence of tendon xanthomas in familial hypercholesterolemia.
Corredoira P; Marco-Benedi V; Cenarro A; Peribáñez S; Olmos S; Civeira F
Rev Esp Cardiol (Engl Ed); 2024 Jun; 77(6):462-470. PubMed ID: 38185215
[TBL] [Abstract][Full Text] [Related]
4. Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH.
Anagnostis P; Rizos CV; Skoumas I; Rallidis L; Tziomalos K; Skalidis E; Kotsis V; Doumas M; Kolovou G; Sfikas G; Garoufi A; Lambadiari V; Dima I; Kiouri E; Agapakis D; Zacharis E; Antza C; Kolovou V; Koumaras C; Bantouvakis G; Liamis G; Liberopoulos EN
Endocrine; 2022 May; 76(2):324-330. PubMed ID: 35262845
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Diabetes and Its Association with Atherosclerotic Cardiovascular Disease Risk in Patients with Familial Hypercholesterolemia: An Analysis from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
Boutari C; Rizos CV; Doumas M; Liamis G; Skoumas I; Rallidis L; Garoufi A; Kolovou G; Tziomalos K; Skalidis E; Kotsis V; Sfikas G; Lambadiari V; Anagnostis P; Bilianou E; Anastasiou G; Koutagiar I; Kiouri E; Attilakos A; Kolovou V; Zacharis E; Antza C; Liberopoulos E
Pharmaceuticals (Basel); 2022 Dec; 16(1):. PubMed ID: 36678541
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels.
Funabashi S; Kataoka Y; Hori M; Ogura M; Doi T; Noguchi T; Harada-Shiba M
J Am Heart Assoc; 2022 Aug; 11(16):e025232. PubMed ID: 35929461
[TBL] [Abstract][Full Text] [Related]
7. Relations of physical signs to genotype, lipid and inflammatory markers, coronary stenosis or calcification, and outcomes in patients with heterozygous familial hypercholesterolemia.
Liu MM; Peng J; Guo YL; Zhu CG; Wu NQ; Xu RX; Dong Q; Li JJ
J Transl Med; 2021 Dec; 19(1):498. PubMed ID: 34876165
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study.
Yamashita S; Masuda D; Harada-Shiba M; Arai H; Bujo H; Ishibashi S; Daida H; Koga N; Oikawa S
J Atheroscler Thromb; 2022 May; 29(5):608-638. PubMed ID: 33980760
[TBL] [Abstract][Full Text] [Related]
9. The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study.
Meshkov AN; Ershova AI; Kiseleva AV; Shalnova SA; Drapkina OM; Boytsov SA; On Behalf Of The Fh-Esse-Rf Investigators
J Pers Med; 2021 May; 11(6):. PubMed ID: 34074024
[TBL] [Abstract][Full Text] [Related]
10. The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia.
Gallo A; Pérez de Isla L; Charrière S; Vimont A; Alonso R; Muñiz-Grijalvo O; Díaz-Díaz JL; Zambón D; Moulin P; Bruckert E; Mata P; Béliard S;
JACC Cardiovasc Imaging; 2021 Dec; 14(12):2414-2424. PubMed ID: 34274263
[TBL] [Abstract][Full Text] [Related]
11. Metabolic systems approaches update molecular insights of clinical phenotypes and cardiovascular risk in patients with homozygous familial hypercholesterolemia.
Du Z; Li F; Jiang L; Li L; Du Y; Yu H; Luo Y; Wang Y; Sun H; Hu C; Li J; Yang Y; Jiao X; Wang L; Qin Y
BMC Med; 2023 Jul; 21(1):275. PubMed ID: 37501168
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Non-coronary Heart Disease in Patients with Familial Hypercholesterolemia: An Analysis from the HELLAS-FH.
Anagnostis P; Rizos CV; Skoumas I; Rallidis L; Tziomalos K; Skalidis E; Kotsis V; Doumas M; Kolovou G; Sfikas G; Bilianou E; Koutagiar I; Agapakis D; Zacharis E; Antza C; Koumaras C; Boutari C; Liamis G; Liberopoulos EN
Curr Pharm Des; 2021; 27(21):2537-2544. PubMed ID: 33593250
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
[TBL] [Abstract][Full Text] [Related]
14. The value of physical signs in identifying patients with familial hypercholesterolemia in the era of genetic testing.
Rallidis LS; Iordanidis D; Iliodromitis E
J Cardiol; 2020 Dec; 76(6):568-572. PubMed ID: 32741655
[TBL] [Abstract][Full Text] [Related]
15. Familial Hypercholesterolemia in the Elderly: An Analysis of Clinical Profile and Atherosclerotic Cardiovascular Disease Burden from the Hellas-FH Registry.
Antza C; Rizos CV; Kotsis V; Liamis G; Skoumas I; Rallidis L; Garoufi A; Kolovou G; Tziomalos K; Skalidis E; Sfikas G; Doumas M; Lambadiari V; Anagnostis P; Stamatelopoulos K; Anastasiou G; Koutagiar I; Kiouri E; Kolovou V; Polychronopoulos G; Zacharis E; Koumaras C; Boutari C; Milionis H; Liberopoulos E
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38275402
[TBL] [Abstract][Full Text] [Related]
16. Stratification in Heterozygous Familial Hypercholesterolemia: Imaging, Biomarkers, and Genetic Testing.
Corral P; Aguilar Salinas CA; Matta MG; Zago V; Schreier L
Curr Atheroscler Rep; 2023 Dec; 25(12):899-909. PubMed ID: 37921916
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular disease prevention in heterozygous familial hypercholesterolemia: how important is a healthy diet in the era of long-lasting cholesterol-lowering drug therapies?
Roy G; Drouin-Chartier JP
Curr Opin Lipidol; 2024 Feb; 35(1):1-6. PubMed ID: 37910156
[TBL] [Abstract][Full Text] [Related]
18. How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?
Kataoka Y; Funabashi S; Doi T; Harada-Shiba M
J Atheroscler Thromb; 2022 Jun; 29(6):795-807. PubMed ID: 35022364
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of familial hypercholesterolemia in patients with confirmed premature coronary artery disease in Ranchi, Jharkhand.
Kumar P; Prasad SR; Anand A; Kumar R; Ghosh S
Egypt Heart J; 2022 Dec; 74(1):83. PubMed ID: 36527449
[TBL] [Abstract][Full Text] [Related]
20. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
Arca M
Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
